N/A. N/A

Inhibitory effect of VEGF antisense oligonucleotide on HT-29 human colorectal cancer cells in vitro

AIM: To investigate the inhibitory effect of vascular endothelial growth factor (VEGF) antisense oligonucleotide (ASODN) on human colorectal cancer cell line HT-29 in vitro.

METHODS: Human colorectal cancer HT-29 cells were transfected with VEGF ASODN and scrambled oligodeoxynueleotide (SODN) by Lipofectamine^TM2000. The expression of VEGF mRNA in HT-29 cells was detected using semi-quantitive reverse transcription-polymerase chain reaction (RT-PCR) and the excretion of VEGF protein was measured by Western blot 48 and 72 hours after transfection. The proliferation and apoptosis of HT-29 cells were measured using MTT assay and flow cytometry respectively.

RESULTS: The expression of VEGF mRNA in HT-29 cells transfected with ASODN was significantly lower 48 h after transfection than that in the plasmid controls or SODN controls (0.455 ± 0.032 vs 0.934 ± 0.031, 0.915 ± 0.004; both P < 0.01). There was no marked difference between the two control groups. The expression of VEGF protein in HT-29 cells was confirmed and the specific band on PVDF membrane in the ASODN group was obviously weaker than that in the control groups. VEGF ASOND inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner (P < 0.05); the apoptotic index of HT-29 cells in the ASODN group was obviously higher than that in the control groups (P < 0.05) 72 h after transfection.

CONCLUSION: VEGF ASODN can inhibit the proliferation and induce the apoptosis of HT-29 cells in vitro by inhibiting VEGF gene expression.

Effects of vascular endothelial growth factor antisense oligodeoxynucleotide on the mRNA expression of vascular endothelial growth factor, fms-like tyrosine kinase-1 and kinase insert domain-containing receptor and vascular endothelial growth factor protein excretion of gallbladder carcinoma GBC-SD cells in vitro

AIM: To investigate the effect of oligofectamine-mediated vascular endothelial growth factor (VEGF) antisense oligodeoxynucleotide (ASODN) transfection on the mRNA expression of VEGF, fms-like tyrosine kinase-1 (Flt-1) and kinase insert domain-containing receptor (KDR) as well as VEGF protein excretion of gallbladder carcinoma GBC-SD cells in vitro.

METHODS: Gallbladder carcinoma GBC-SD cells were transfected with VEGF ASODN and scrambled oligodeoxynucleotide (SODN) by Oligofectamine mediation. The mRNA expression of VEGF, Flt-1 and KDR in GBC-SD cells of each group were detected by semi-quantitive reverse transcription-polymerase chain reaction (RT-PCR) and the excretion of VEGF protein was measured by enzyme-linked immunosorbent assay (ELISA).

RESULTS: Semi-quantitive RT-PCR revealed that VEGF, Flt-1 and KDR mRNA expression in groups of ASODN (VEGF165: 0.686 ± 0.033, 0.569 ± 0.049, 0.489 ± 0.036, 0.716 ± 0.017; VEGF165: 0.462 ± 0.046, 0.338 ± 0.034, 0.219 ± 0.022, 0.471 ± 0.038; Flt-1: 0.694 ± 0.019, 0.562 ± 0.045, 0.435 ± 0.042, 0.724 ± 0.026; KDR: 0.667 ± 0.063, 0.490 ± 0.033, 0.301 ± 0.029, 0.665 ± 0.068) and ASODN + Oligofectamine (VEGF165: 0.601 ± 0.021, 0.465 ± 0.042, 0.416 ± 0.023, 0.662 ± 0.035; VEGF121: 0.408 ± 0.014, 0.286 ± 0.019, 0.157 ± 0.021, 0.418 ± 0.037; Flt-1: 0.609 ± 0.018, 0.442 ± 0.049, 0.314 ± 0.015, 0.614 ± 0.029; KDR: 0.523 ± 0.048, 0.432 ± 0.027, 0.218 ± 0.036, 0.524 ± 0.037) were significantly inhibited 24, 48, 72 and 96 h after transfection in comparison with those in the control group (P < 0.05), and the inhibitory effect of ASODN + Oligofectamine was stronger (P > 0.05). ELISA results discovered that VEGF protein excretion was markedly decreased in the culture media of ASODN (281.26 ± 18.62, 526.44 ± 34.95, 791.13 ± 20.99) and ASODN + Oligofectamine (250.7 ± 14.57, 506.09 ± 19.14, 711.79 ± 19.91) group (P < 0.05) as compared with that in the control group, and ASODN + Oligofectamine was more efficient (P > 0.05).

CONCLUSION: VEGF ASODN can inhibit VEGF, Flt-1 and KDR mRNA expression and VEGF protein excretion of GBC-SD cells, and the effect may be strengthened by Oligofectamine mediation.